Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Effect of bazedoxifene on expressions of VEGF, VEGFR2, COX-2 and inflammatory factors in a rat endometriosis model

Rui Hou1, Hao Xu2, Hui Li1

1Nursing School, SIAS University of Zhengzhou, Zhengzhou; 2Department of Traditional Chinese Medicine, Affiliated Hangzhou First Peoples Hospital, Zhejiang University School of Medicine, Hanzghou City 310006, China.

For correspondence:-  Hui Li   Email: ziy8xg@163.com

Accepted: 27 August 2019        Published: 30 September 2019

Citation: Hou R, Xu H, Li H. Effect of bazedoxifene on expressions of VEGF, VEGFR2, COX-2 and inflammatory factors in a rat endometriosis model. Trop J Pharm Res 2019; 18(9):1799-1804 doi: 10.4314/tjpr.v18i9.2

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the effect of bazedoxifene on the expressions of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 2 (sVEGFR2), cyclooxygenase synthase 2 (COX-2) and inflammatory factors in a rat endometriosis (EMS) model.
Methods: Thirty rats (EMS) were divided into untreated control group, bazedoxifene group and celecoxib group (10 rats per group). Bazedoxifene and celecoxib were administered at doses of 3 and 25 mg/kg, respectively. Negative control rats served as control, and were given 0.9 % sodium chloride at a dose of 10 mL/kg. All treatments were given intragastrically for 21 days. Levels of VEGF, sVEGFR2 and COX-2 in uterine ectopic endometrium were assayed.
Results: The levels of VEGF and sVEGFR2 in the serum and peritoneal fluid of the untreated control group were significantly higher than the corresponding control values, while VEGF and sVEGFR2 levels in the serum and peritoneal fluid of the bazedoxifene group were significantly lower than those in the untreated control group (p < 0.05). Bazedoxifene group had lower VEGFR2 and COX-2 levels than untreated control group (p < 0.05). expression of COX-2 protein in the ectopic endometrium of celecoxib group was significantly lower than that in the untreated control group (p < 0.05).
Conclusion: Bazedoxifene alleviates angiogenesis and inflammatory factors in serum and peritoneal fluid of EMS rats, inhibits the expression of sVEGFR2 and COX-2 in ectopic endometrium, and also inhibits the growth of ectopic endometrium. This finding may help to discover additional new drugs.

Keywords: Bazedoxifene, Endometriosis, VEGF, VEGFR2, COX-2, Inflammatory factors

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates